Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of CG-549 Tablet in Healthy Subjects
NCT05393856Phase 1Completed
- Sponsor
- Crystal Genomics
- Start
- Sep 2019
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of nilofabicin in Staphylococcus aureus infection (3 arms), sponsored by Crystal Genomics. Primary endpoints: Maximum Observed Plasma Concentration up to 4 weeks and Area Under the Concentration-Time Curve up to 4 weeks. Started Sep 2019; status: completed.
02
Drugs
nilofabicin
03
Conditions
Staphylococcus aureus infection
Beyond the preview
Go deeper on NCT05393856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05393856.